Lumos Diagnostics Holdings Ltd - Asset Resilience Ratio
Lumos Diagnostics Holdings Ltd (LDX) has an Asset Resilience Ratio of 14.18% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2024)
This chart shows how Lumos Diagnostics Holdings Ltd's Asset Resilience Ratio has changed over time. Check asset allocation strategy of Lumos Diagnostics Holdings Ltd to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Lumos Diagnostics Holdings Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Lumos Diagnostics Holdings Ltd worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$2.99 Million | 14.18% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$2.99 Million | 14.18% |
Asset Resilience Insights
- Moderate Liquidity: Lumos Diagnostics Holdings Ltd has 14.18% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Lumos Diagnostics Holdings Ltd Industry Peers by Asset Resilience Ratio
Compare Lumos Diagnostics Holdings Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 12.59% |
|
INKON Life Technology Co Ltd
SHE:300143 |
Medical Devices | 5.73% |
|
Scibase AB
ST:SCIB |
Medical Devices | 43.33% |
|
T&L Co. Ltd
KQ:340570 |
Medical Devices | 33.68% |
|
Tellgen Corp
SHE:300642 |
Medical Devices | 9.96% |
|
Affluent Medical SAS
PA:AFME |
Medical Devices | 0.03% |
|
Vieworks Co. Ltd
KQ:100120 |
Medical Devices | 7.81% |
Annual Asset Resilience Ratio for Lumos Diagnostics Holdings Ltd (2017–2024)
The table below shows the annual Asset Resilience Ratio data for Lumos Diagnostics Holdings Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 9.40% | AU$1.96 Million ≈ $1.38 Million |
AU$20.81 Million ≈ $14.73 Million |
-14.74pp |
| 2023-12-31 | 24.14% | AU$6.48 Million ≈ $4.58 Million |
AU$26.84 Million ≈ $18.99 Million |
+12.28pp |
| 2022-12-31 | 11.86% | AU$3.02 Million ≈ $2.13 Million |
AU$25.42 Million ≈ $17.99 Million |
-9.74pp |
| 2021-12-31 | 21.60% | AU$7.98 Million ≈ $5.64 Million |
AU$36.94 Million ≈ $26.14 Million |
-24.21pp |
| 2020-12-31 | 45.81% | AU$44.89 Million ≈ $31.76 Million |
AU$97.99 Million ≈ $69.33 Million |
+43.00pp |
| 2019-12-31 | 2.81% | AU$850.30K ≈ $601.64K |
AU$30.28 Million ≈ $21.42 Million |
-9.05pp |
| 2018-12-31 | 11.86% | AU$3.01 Million ≈ $2.13 Million |
AU$25.40 Million ≈ $17.97 Million |
+9.31pp |
| 2017-12-31 | 2.55% | AU$226.43K ≈ $160.21K |
AU$8.89 Million ≈ $6.29 Million |
-- |
About Lumos Diagnostics Holdings Ltd
Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company's products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, … Read more